• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Cannabis Market
    Cannabis News
    Cannabis Stocks
    • Cannabis Market
    • Cannabis News
    • Cannabis Stocks
    cannabis investing

    Tetra Bio-Pharma Signs Commercialization Deal for PPP001 in Israel

    Bryan Mc Govern
    Apr. 24, 2018 08:36AM PST
    Cannabis Investing News

    Tetra Bio-Pharma announced the signing of a first binding term sheet for the marketing and distribution of its product PPP001 in Israel with Kamada, a pharmaceutical company.

    Tetra Bio-Pharma (TSXV:TBP; OTCQB:TBPMF) announced the signing of a first binding term sheet for the marketing and distribution of its product PPP001 in Israel with Kamada, a pharmaceutical company.

    As quoted in the press release:

    The signing of a Definitive Distribution Agreement is expected to follow shortly. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.

    This first international market commercialization agreement represents a significant milestone and a validation of Tetra Bio-Pharma’s business model with a leading Israel-based pharmaceutical company. Israel, like Canada, is considered one of the world leaders in the production and development of cannabinoid-based products. Kamada is a company with two FDA-approved products and an Israeli-based distribution segment that has demonstrated continued growth. Tetra Bio-Pharma intends to work closely with Kamada as PPP001 advances towards regulatory approval and commercial launch in Israel.

    Click here to read the full press release.

    Source: www.marketwired.com

    distribution agreementa pharmaceutical companycannabis investinginternational marketcanada
    The Conversation (0)

    Go Deeper

    AI Powered
    VIDEO Round-Up BBHIC 2019

    VIDEO Round-Up BBHIC 2019

    Tetra Bio-Pharma Enters Into Medical Cannabis Supply Agreement With ACMPR Licensed Producer Aphria Inc.

    Latest News

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Cannabis Investing News Stocks

    The Tinley Beverage Company

    BKTS:CC

    extractX

    Hygrovest Limited

    HGV:AU

    Lords & Company Worldwide Holdings

    LRDS:CNX
    Lords & Company Worldwide Holdings Logo

    Adastra Holdings

    XTRX:CNX

    MMJ Group Holdings

    MMJ:AU
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES